AEON Biopharma Regains NYSE American Listing Compliance After $13.6 Million Public Offering Strengthens Shareholders' Equity

AEON Biopharma, Inc., a biopharmaceutical company developing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use, has regained compliance with the NYSE American's continued listing standards related to shareholders' equity. The company said it received written confirmation from NYSE American that it has resolved the previously identified compliance issues and will continue trading under the exchange's standard listing requirements.

On August 3, 2026, AEON received a letter from NYSE Regulation confirming that it had addressed the deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide. As a result, the ".BC" indicator that had been attached to the company's trading symbol is expected to be removed, and AEON will also be taken off the exchange's list of noncompliant issuers. The company said it will remain subject to the NYSE American's regular listing monitoring procedures and will continue focusing on maintaining strong financial discipline and corporate governance.

The company regained compliance following the successful completion of its underwritten public offering in July 2026. On July 15, AEON closed the offering of 17.85 million shares of common stock and pre-funded warrants to purchase approximately 24.84 million additional shares. Each share or pre-funded warrant was issued together with both a two-year milestone warrant and a five-year milestone warrant, each allowing the purchase of one additional share of common stock. On July 23, the company also issued an additional 4.7 million shares after the underwriters partially exercised their over-allotment option.

AEON reported net proceeds of approximately $13.6 million from the offering after underwriting discounts, commissions, and related expenses. The company also said it could receive up to an additional $34 million in gross proceeds if all of the milestone warrants issued as part of the financing are exercised for cash. Following the completion of the offering, AEON believes its shareholders' equity now exceeds the NYSE American's minimum requirement of $4 million, allowing it to meet the exchange's continued listing standards.

The company noted that because the public offering closed after the end of its second fiscal quarter, the unaudited balance sheet as of June 30, 2026, included in its upcoming quarterly report on Form 10-Q will still show a shareholders' deficit. However, the financial impact of the completed financing will be reported as a subsequent event and will not affect the company's restored compliance status.

AEON is advancing ABP-450 as a biosimilar version of BOTOX® with the goal of achieving full-label approval in the U.S. market for therapeutic indications. The restoration of its NYSE American compliance strengthens the company's financial position as it continues to support the development and commercialization of its lead product candidate.